Nanoparticles Targeting Macrophages for Enhancement of Macrophage Phagocytosis in Cancer Immunotherapy

Chapter1

[1] Weiskopf K, Weissman IL. Macrophages are critical effectors of antibody therapies for cancer. MAbs. 2015;7:303-10.

[2] Uribe-Querol E, Rosales C. Phagocytosis: Our Current Understanding of a Universal Biological Process. Frontiers in immunology. 2020;11.

[3] Espinosa V, Rivera A. First Line of Defense: Innate Cell-Mediated Control of Pulmonary Aspergillosis. Frontiers in microbiology. 2016;7.

[4] Guha I, Naskar D, Sen M. Macrophage as a mediator of immune response: Sustenance of immune homeostasis. 2015.

[5] Chistiakov DA, Bobryshev YV, Orekhov AN. Changes in transcriptome of macrophages in atherosclerosis. Journal of cellular and molecular medicine. 2015;19:1163-73.

[6] Sheikhpour E, Noorbakhsh P, Foroughi E, Farahnak S, Nasiri R, Neamatzadeh H. A Survey on the Role of Interleukin-10 in Breast Cancer: A Narrative. Rep Biochem Mol Biol. 2018;7:30-7.

[7] Yoshimura A, Muto G. TGFβ function in immune suppression. Current topics in microbiology and immunology. 2011;350:127-47.

[8] Pedraza-Brindis EJ, Sanchez-Reyes K, Hernandez-Flores G, Bravo-Cuellar A, Jave- Suarez LF, Aguilar-Lemarroy A, et al. Culture supernatants of cervical cancer cells induce an M2 phenotypic profile in THP-1 macrophages. Cellular immunology. 2016;310:42-52.

[9] Nikonova A, Khaitov M, Jackson DJ, Traub S, Trujillo-Torralbo M-B, Kudlay DA, et al. M1-like macrophages are potent producers of anti-viral interferons and M1- associated marker-positive lung macrophages are decreased during rhinovirus-induced asthma exacerbations. EBioMedicine. 2020;54.

[10] Zanganeh S, Hutter G, Spitler R, Lenkov O, Mahmoudi M, Shaw A, et al. Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. Nature nanotechnology. 2016;11:986-94.

[11] Hao Z, Li R, Meng L, Han Z, Hong Z. Macrophage, the potential key mediator in CAR-T related CRS. Exp Hematol Oncol. 2020;9:15-.

[12] Sunderkötter C, Steinbrink K, Goebeler M, Bhardwaj R, Sorg C. Macrophages and angiogenesis. J Leukoc Biol. 1994;55:410-22.

[13] Sindrilaru A, Peters T, Wieschalka S, Baican C, Baican A, Peter H, et al. An unrestrained proinflammatory M1 macrophage population induced by iron impairs wound healing in humans and mice. J Clin Invest. 2011;121:985-97.

[14] Wynn TA, Vannella KM. Macrophages in Tissue Repair, Regeneration, and Fibrosis. Immunity. 2016;44:450-62.

[15] Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nature reviews Clinical oncology. 2017;14:399-416.

[16] Dugo L, Belluomo MG, Fanali C, Russo M, Cacciola F, Maccarrone M, et al. Effect of Cocoa Polyphenolic Extract on Macrophage Polarization from Proinflammatory M1 to Anti-Inflammatory M2 State. Oxidative medicine and cellular longevity. 2017;2017:6293740.

[17] Matsuura M, Kiso M, Hasegawa A. Activity of Monosaccharide Lipid A Analogues in Human Monocytic Cells as Agonists or Antagonists of Bacterial Lipopolysaccharide. Infection and immunity. 1999;67:6286-92.

[18] Nikoofal-Sahlabadi S, Matbou Riahi M, Sadri K, Badiee A, Nikpoor AR, Jaafari MR. Liposomal CpG-ODN: An in vitro and in vivo study on macrophage subtypes responses, biodistribution and subsequent therapeutic efficacy in mice models of cancers. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2018;119:159-70.

[19] Fernandez PL, Dutra FF, Alves L, Figueiredo RT, Mourao-Sa D, Fortes GB, et al. Heme amplifies the innate immune response to microbial molecules through spleen tyrosine kinase (Syk)-dependent reactive oxygen species generation. The Journal of biological chemistry. 2010;285:32844-51.

[20] Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance. Journal of cell science. 2012;125:5591-6.

[21] Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nature medicine. 2018;24:541-50.

[22] Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clinical orthopaedics and related research. 1991:3-11.

[23] Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nature Reviews Immunology. 2020;20:651-68.

[24] Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nature Reviews Clinical Oncology. 2020;17:147-67.

[25] Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nature communications. 2020;11:3801.

[26] Hollingsworth RE, Jansen K. Turning the corner on therapeutic cancer vaccines. npj Vaccines. 2019;4:7.

[27] Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nature Reviews Immunology. 2010;10:317-27.

[28] Fontana F, Figueiredo P, Bauleth-Ramos T, Correia A, Santos HA. Immunostimulation and Immunosuppression: Nanotechnology on the Brink. Small Methods. 2018;2:1700347.

[29] Gul N, van Egmond M. Antibody-Dependent Phagocytosis of Tumor Cells by Macrophages: A Potent Effector Mechanism of Monoclonal Antibody Therapy of Cancer. Cancer research. 2015;75:5008-13.

[30] Shi Y, Fan X, Deng H, Brezski RJ, Rycyzyn M, Jordan RE, et al. Trastuzumab triggers phagocytic killing of high HER2 cancer cells in vitro and in vivo by interaction with Fcγ receptors on macrophages. Journal of immunology (Baltimore, Md : 1950). 2015;194:4379-86.

[31] Kelly C, Jefferies C, Cryan SA. Targeted liposomal drug delivery to monocytes and macrophages. Journal of drug delivery. 2011;2011:727241.

[32] Patel SK, Janjic JM. Macrophage targeted theranostics as personalized nanomedicine strategies for inflammatory diseases. Theranostics. 2015;5:150-72.

[33] Wilczewska AZ, Niemirowicz K, Markiewicz KH, Car H. Nanoparticles as drug delivery systems. Pharmacological reports : PR. 2012;64:1020-37.

[34] Sarmento B, Mazzaglia D, Bonferoni MC, Neto AP, do Céu Monteiro M, Seabra V. Effect of chitosan coating in overcoming the phagocytosis of insulin loaded solid lipid nanoparticles by mononuclear phagocyte system. Carbohydrate polymers. 2011;84:919-25.

[35] Yamada T, Iwasaki Y, Tada H, Iwabuki H, Chuah MK, VandenDriessche T, et al. Nanoparticles for the delivery of genes and drugs to human hepatocytes. Nature biotechnology. 2003;21:885-90.

[36] Yamada M, Oeda A, Jung J, Iijima M, Yoshimoto N, Niimi T, et al. Hepatitis B virus envelope L protein-derived bio-nanocapsules: mechanisms of cellular attachment and entry into human hepatic cells. Journal of controlled release : official journal of the Controlled Release Society. 2012;160:322-9.

Chapter 2

[1] Davies LC, Jenkins SJ, Allen JE, Taylor PR. Tissue-resident macrophages. Nature immunology 2013;14:986-95.

[2] Baron R. Molecular mechanisms of bone resorption by the osteoclast. The Anatomical Record 1989;224:317-24.

[3] Harre U, Lang SC, Pfeifle R, Rombouts Y, Fruhbeisser S, Amara K, Bang H, Lux A, Koeleman CA, Baum W, Dietel K, Grohn F, Malmstrom V, Klareskog L, Kronke G, Kocijan R, Nimmerjahn F, Toes RE, Herrmann M, Scherer HU, Schett G. Glycosylation of immunoglobulin G determines osteoclast differentiation and bone loss. Nature communications 2015;6:6651.

[4] Kelly C, Jefferies C, Cryan SA. Targeted liposomal drug delivery to monocytes and macrophages. Journal of drug delivery 2011;2011:727241.

[5] Patel SK, Janjic JM. Macrophage targeted theranostics as personalized nanomedicine strategies for inflammatory diseases. Theranostics 2015;5:150-72.

[6] Laria A, Lurati A, Marrazza M, Mazzocchi D, Re KA, Scarpellini M. The macrophages in rheumatic diseases. Journal of Inflammation Research 2016;9:1-11.

[7] Moore KJ, Sheedy FJ, Fisher EA. Macrophages in atherosclerosis: a dynamic balance. Nature reviews Immunology 2013;13:709-21.

[8] Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity 2014;41:49-61.

[9] Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nature reviews Clinical oncology 2017;14:399-416.

[10] Apostolopoulos V, Thalhammer T, Tzakos AG, Stojanovska L. Targeting antigens to dendritic cell receptors for vaccine development. Journal of drug delivery 2013;2013:869718.

[11] Blanco P, Palucka AK, Pascual V, Banchereau J. Dendritic cells and cytokines in human inflammatory and autoimmune diseases. Cytokine & growth factor reviews 2008;19:41-52.

[12] Worbs T, Hammerschmidt SI, Forster R. Dendritic cell migration in health and disease. Nature reviews Immunology 2017;17:30-48.

[13] Ferenbach D, Hughes J. Macrophages and dendritic cells: what is the difference? Kidney international 2008;74:5-7.

[14] Singh Y, Pawar VK, Meher JG, Raval K, Kumar A, Shrivastava R, Bhadauria S, Chourasia MK. Targeting tumor associated macrophages (TAMs) via nanocarriers. Journal of controlled release : official journal of the Controlled Release Society 2017.

[15] Kim M-G, Park JY, Shon Y, Kim G, Shim G, Oh Y-K. Nanotechnology and vaccine development. Asian Journal of Pharmaceutical Sciences 2014;9:227-35.

[16] Matsuo H, Yoshimoto N, Iijima M, Niimi T, Jung J, Jeong SY, Choi EK, Sewaki T, Arakawa T, Kuroda S. Engineered hepatitis B virus surface antigen L protein particles for in vivo active targeting of splenic dendritic cells. Int J Nanomedicine 2012;7:3341- 50.

[17] Champion JA, Walker A, Mitragotri S. Role of Particle Size in Phagocytosis of Polymeric Microspheres. Pharmaceutical research 2008;25:1815-21.

[18] Pacheco P, White D, Sulchek T. Effects of Microparticle Size and Fc Density on Macrophage Phagocytosis. PLoS ONE 2013;8:e60989.

[19] Yue H, Wei W, Yue Z, Lv P, Wang L, Ma G, Su Z. Particle size affects the cellular response in macrophages. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2010;41:650-7.

[20] Kou L, Sun J, Zhai Y, He Z. The endocytosis and intracellular fate of nanomedicines: Implication for rational design. Asian Journal of Pharmaceutical Sciences 2013;8:1-10.

[21] Oyewumi MO, Kumar A, Cui Z. Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert review of vaccines 2010;9:1095-107.

[22] Guilliams M, Bruhns P, Saeys Y, Hammad H, Lambrecht BN. The function of Fcγ receptors in dendritic cells and macrophages. Nature reviews Immunology 2014;14:94- 108.

[23] Freeman SA, Grinstein S. Phagocytosis: receptors, signal integration, and the cytoskeleton. Immunological Reviews 2014;262:193-215.

[24] Alwan HA, van Zoelen EJ, van Leeuwen JE. Ligand-induced lysosomal epidermal growth factor receptor (EGFR) degradation is preceded by proteasome-dependent EGFR de-ubiquitination. The Journal of biological chemistry 2003;278:35781-90.

[25] Henriksen L, Grandal MV, Knudsen SLJ, van Deurs B, Grøvdal LM. Internalization Mechanisms of the Epidermal Growth Factor Receptor after Activation with Different Ligands. PLoS ONE 2013;8:e58148.

[26] Chamberland JP, Antonow LT, Dias Santos M, Ritter B. NECAP2 controls clathrin coat recruitment to early endosomes for fast endocytic recycling. Journal of cell science 2016;129:2625-37.

[27] Francavilla C, Papetti M, Rigbolt KT, Pedersen AK, Sigurdsson JO, Cazzamali G, Karemore G, Blagoev B, Olsen JV. Multilayered proteomics reveals molecular switches dictating ligand-dependent EGFR trafficking. Nature structural & molecular biology 2016;23:608-18.

[28] Kuroda S, Otaka S, Miyazaki T, Nakao M, Fujisawa Y. Hepatitis B virus envelope L protein particles. Synthesis and assembly in Saccharomyces cerevisiae, purification and characterization. The Journal of biological chemistry 1992;267:1953-61.

[29] Yamada T, Iwasaki Y, Tada H, Iwabuki H, Chuah MK, VandenDriessche T, Fukuda H, Kondo A, Ueda M, Seno M, Tanizawa K, Kuroda S. Nanoparticles for the delivery of genes and drugs to human hepatocytes. Nature biotechnology 2003;21:885-90.

[30] Li H, Onbe K, Liu Q, Iijima M, Tatematsu K, Seno M, Tada H, Kuroda SI. Synthesis and assembly of Hepatitis B virus envelope protein-derived particles in Escherichia coli. Biochemical and biophysical research communications 2017;490:155-60.

[31] Liu Q, Jung J, Somiya M, Iijima M, Yoshimoto N, Niimi T, Maturana AD, Shin SH, Jeong SY, Choi EK, Kuroda S. Virosomes of hepatitis B virus envelope L proteins containing doxorubicin: synergistic enhancement of human liver-specific antitumor growth activity by radiotherapy. Int J Nanomedicine 2015;10:4159-72.

[32] Somiya M, Yamaguchi K, Liu Q, Niimi T, Maturana AD, Iijima M, Yoshimoto N, Kuroda S. One-step scalable preparation method for non-cationic liposomes with high siRNA content. International journal of pharmaceutics 2015;490:316-23.

[33] Kasuya T, Nomura S, Matsuzaki T, Jung J, Yamada T, Tatematsu K, Okajima T, Tanizawa K, Kuroda S. Expression of squamous cell carcinoma antigen-1 in liver enhances the uptake of hepatitis B virus envelope-derived bio-nanocapsules in transgenic rats. The FEBS journal 2008;275:5714-24.

[34] Kasuya T, Yamada T, Uyeda A, Matsuzaki T, Okajima T, Tatematsu K, Tanizawa K, Kuroda S. In vivo protein delivery to human liver-derived cells using hepatitis B virus envelope pre-S region. Journal of bioscience and bioengineering 2008;106:99- 102.

[35] Kurata N, Shishido T, Muraoka M, Tanaka T, Ogino C, Fukuda H, Kondo A. Specific protein delivery to target cells by antibody-displaying bionanocapsules. Journal of biochemistry 2008;144:701-7.

[36] Iijima M, Matsuzaki T, Kadoya H, Hatahira S, Hiramatsu S, Jung G, Tanizawa K, Kuroda S. Bionanocapsule-based enzyme-antibody conjugates for enzyme-linked immunosorbent assay. Analytical biochemistry 2010;396:257-61.

[37] Tsutsui Y, Tomizawa K, Nagita M, Michiue H, Nishiki T, Ohmori I, Seno M, Matsui H. Development of bionanocapsules targeting brain tumors. Journal of controlled release : official journal of the Controlled Release Society 2007;122:159-64.

[38] Erntell M, Myhre EB, Sjobring U, Bjorck L. Streptococcal protein G has affinity for both Fab- and Fc-fragments of human IgG. Molecular immunology 1988;25:121-6.

[39] Nilson BH, Solomon A, Bjorck L, Akerstrom B. Protein L from Peptostreptococcus magnus binds to the kappa light chain variable domain. The Journal of biological chemistry 1992;267:2234-9.

[40] Graille M, Stura EA, Housden NG, Beckingham JA, Bottomley SP, Beale D, Taussig MJ, Sutton BJ, Gore MG, Charbonnier JB. Complex between Peptostreptococcus magnus protein L and a human antibody reveals structural convergence in the interaction modes of Fab binding proteins. Structure (London, England : 1993) 2001;9:679-87.

[41] Tatematsu K, Iijima M, Yoshimoto N, Nakai T, Okajima T, Kuroda S. Bio- nanocapsules displaying various immunoglobulins as an active targeting-based drug delivery system. Acta biomaterialia 2016;35:238-47.

[42] Jung J, Iijima M, Yoshimoto N, Sasaki M, Niimi T, Tatematsu K, Jeong SY, Choi EK, Tanizawa K, Kuroda S. Efficient and rapid purification of drug- and gene-carrying bio-nanocapsules, hepatitis B virus surface antigen L particles, from Saccharomyces cerevisiae. Protein expression and purification 2011;78:149-55.

[43] Sato JD, Kawamoto T, Le AD, Mendelsohn J, Polikoff J, Sato GH. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Molecular biology & medicine 1983;1:511-29.

[44] Zhigaltsev IV, Belliveau N, Hafez I, Leung AK, Huft J, Hansen C, Cullis PR. Bottom-up design and synthesis of limit size lipid nanoparticle systems with aqueous and triglyceride cores using millisecond microfluidic mixing. Langmuir : the ACS journal of surfaces and colloids 2012;28:3633-40.

[45] Haran G, Cohen R, Bar LK, Barenholz Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochimica et biophysica acta 1993;1151:201-15.

[46] Lasic DD, Ceh B, Stuart MC, Guo L, Frederik PM, Barenholz Y. Transmembrane gradient driven phase transitions within vesicles: lessons for drug delivery. Biochimica et biophysica acta 1995;1239:145-56.

[47] Yamada M, Oeda A, Jung J, Iijima M, Yoshimoto N, Niimi T, Jeong SY, Choi EK, Tanizawa K, Kuroda S. Hepatitis B virus envelope L protein-derived bio-nanocapsules: mechanisms of cellular attachment and entry into human hepatic cells. Journal of controlled release : official journal of the Controlled Release Society 2012;160:322-9.

[48] Iijima M, Somiya M, Yoshimoto N, Niimi T, Kuroda S. Nano-visualization of oriented-immobilized IgGs on immunosensors by high-speed atomic force microscopy. Scientific reports 2012;2:790.

[49] Iijima M, Kadoya H, Hatahira S, Hiramatsu S, Jung G, Martin A, Quinn J, Jung J, Jeong SY, Choi EK, Arakawa T, Hinako F, Kusunoki M, Yoshimoto N, Niimi T, Tanizawa K, Kuroda S. Nanocapsules incorporating IgG Fc-binding domain derived from Staphylococcus aureus protein A for displaying IgGs on immunosensor chips. Biomaterials 2011;32:1455-64.

[50] Hirano M, Davis RS, Fine WD, Nakamura S, Shimizu K, Yagi H, Kato K, Stephan RP, Cooper MD. IgEb immune complexes activate macrophages through FcγRIV binding. Nature immunology 2007;8:762-71.

[51] Somiya M, Sasaki Y, Matsuzaki T, Liu Q, Iijima M, Yoshimoto N, Niimi T, Maturana AD, Kuroda S. Intracellular trafficking of bio-nanocapsule-liposome complex: Identification of fusogenic activity in the pre-S1 region of hepatitis B virus surface antigen L protein. Journal of controlled release : official journal of the Controlled Release Society 2015;212:10-8.

[52] Liu Q, Somiya M, Shimada N, Sakamoto W, Yoshimoto N, Iijima M, Tatematsu K, Nakai T, Okajima T, Maruyama A, Kuroda S. Mutational analysis of hepatitis B virus pre-S1 (9-24) fusogenic peptide. Biochemical and biophysical research communications 2016;474:406-12.

[53] Mercer J, Helenius A. Virus entry by macropinocytosis. Nat Cell Biol 2009;11:510-20.

Chapter 3

[1] Kim R, Emi M, Tanabe K. Cancer cell immune escape and tumor progression by exploitation of anti-inflammatory and pro-inflammatory responses. Cancer Biology & Therapy. 2014;4:924-33.

[2] Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nature reviews Clinical oncology. 2017;14:399-416.

[3] Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014;41:49-61.

[4] Zanganeh S, Hutter G, Spitler R, Lenkov O, Mahmoudi M, Shaw A, et al. Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. Nature nanotechnology. 2016;11:986-94.

[5] Yang L, Zhang Y. Tumor-associated macrophages: from basic research to clinical application. Journal of hematology & oncology. 2017;10:58.

[6] Chistiakov DA, Bobryshev YV, Orekhov AN. Changes in transcriptome of macrophages in atherosclerosis. Journal of cellular and molecular medicine. 2015;19:1163-73.

[7] Sheikhpour E, Noorbakhsh P, Foroughi E, Farahnak S, Nasiri R, Neamatzadeh H. A Survey on the Role of Interleukin-10 in Breast Cancer: A Narrative. Rep Biochem Mol Biol. 2018;7:30-7.

[8] Yoshimura A, Muto G. TGF-beta function in immune suppression. Current topics in microbiology and immunology. 2011;350:127-47.

[9] Singh Y, Pawar VK, Meher JG, Raval K, Kumar A, Shrivastava R, et al. Targeting tumor associated macrophages (TAMs) via nanocarriers. Journal of controlled release : official journal of the Controlled Release Society. 2017;254:92-106.

[10] Gordon SR, Maute RL, Dulken BW, Hutter G, George BM, McCracken MN, et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017;545:495-9.

[11] Mercer J, Helenius A. Virus entry by macropinocytosis. Nat Cell Biol. 2009;11:510-20.

[12] Zhang F, Wang H, Wang X, Jiang G, Liu H, Zhang G, et al. TGF-β induces M2- like macrophage polarization via SNAIL-mediated suppression of a pro-inflammatory phenotype. Oncotarget. 2016;7:52294-306.

[13] Komohara Y, Horlad H, Ohnishi K, Ohta K, Makino K, Hondo H, et al. M2 macrophage/microglial cells induce activation of Stat3 in primary central nervous system lymphoma. Journal of clinical and experimental hematopathology : JCEH. 2011;51:93-9.

[14] Sharma V, Knobloch TJ, Benjamin D. Differential expression of cytokine genes in HIV-1 tat transfected T and B cell lines. Biochemical and biophysical research communications. 1995;208:704-13.

[15] Yang L, Wang F, Wang L, Huang L, Wang J, Zhang B, et al. CD163+ tumor- associated macrophage is a prognostic biomarker and is associated with therapeutic effect on malignant pleural effusion of lung cancer patients. Oncotarget. 2015;6:10592- 603.

[16] Zhang X, Tian W, Cai X, Wang X, Dang W, Tang H, et al. Hydrazinocurcumin Encapsuled nanoparticles ""re-educate"" tumor-associated macrophages and exhibit anti- tumor effects on breast cancer following STAT3 suppression. PLoS One. 2013;8:e65896.

[17] Wang C, Hu Z, Zhu Z, Zhang X, Wei Z, Zhang Y, et al. The MSHA strain of Pseudomonas aeruginosa (PA-MSHA) inhibits gastric carcinoma progression by inducing M1 macrophage polarization. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2016;37:6913-21. [18] Leblond MM, Gerault AN, Corroyer-Dulmont A, MacKenzie ET, Petit E, Bernaudin M, et al. Hypoxia induces macrophage polarization and re-education toward an M2 phenotype in U87 and U251 glioblastoma models. Oncoimmunology. 2016;5:e1056442.

[19] Genard G, Lucas S, Michiels C. Reprogramming of Tumor-Associated Macrophages with Anticancer Therapies: Radiotherapy versus Chemo- and Immunotherapies. Frontiers in immunology. 2017;8:828.

[20] Weiskopf K, Ring AM, Ho CCM, Volkmer J-P, Levin AM, Volkmer AK, et al. Engineered SIRPα Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies. Science. 2013;341:88.

[21] Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, et al. Anti- CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non- Hodgkin lymphoma. Cell. 2010;142:699-713.

[22] Shi Y, Fan X, Deng H, Brezski RJ, Rycyzyn M, Jordan RE, et al. Trastuzumab triggers phagocytic killing of high HER2 cancer cells in vitro and in vivo by interaction with Fcγ receptors on macrophages. Journal of immunology (Baltimore, Md : 1950). 2015;194:4379-86.

[23] Kurdi AT, Glavey SV, Bezman NA, Jhatakia A, Guerriero JL, Manier S, et al.Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab. Molecular cancer therapeutics. 2018;17:1454-63.

[24] Sockolosky JT, Dougan M, Ingram JR, Ho CCM, Kauke MJ, Almo SC, et al. Durable antitumor responses to CD47 blockade require adaptive immune stimulation. Proceedings of the National Academy of Sciences. 2016;113:E2646.

[25] Leidi M, Gotti E, Bologna L, Miranda E, Rimoldi M, Sica A, et al. M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro. Journal of immunology (Baltimore, Md : 1950). 2009;182:4415-22.

[26] Weiskopf K, Weissman IL. Macrophages are critical effectors of antibody therapies for cancer. MAbs. 2015;7:303-10.

[27] Qie Y, Yuan H, von Roemeling CA, Chen Y, Liu X, Shih KD, et al. Surface modification of nanoparticles enables selective evasion of phagocytic clearance by distinct macrophage phenotypes. Scientific reports. 2016;6:26269.

[28] Herter S, Birk MC, Klein C, Gerdes C, Umana P, Bacac M. Glycoengineering of Therapeutic Antibodies Enhances Monocyte/Macrophage-Mediated Phagocytosis and Cytotoxicity. The Journal of Immunology. 2014;192:2252.

[29] Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, et al. Small anti- viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nature immunology. 2002;3:196-200.

[30] Jurk M, Heil F, Vollmer J, Schetter C, Krieg AM, Wagner H, et al. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nature immunology. 2002;3:499.

[31] Cheadle EJ, Lipowska-Bhalla G, Dovedi SJ, Fagnano E, Klein C, Honeychurch J, et al. A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells. Leukemia. 2017;31:1611-21.

[32] Rodell CB, Arlauckas SP, Cuccarese MF, Garris CS, Li R, Ahmed MS, et al. TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy. Nature Biomedical Engineering. 2018.

[33] Hasham MG, Baxan N, Stuckey DJ, Branca J, Perkins B, Dent O, et al. Systemic autoimmunity induced by the TLR7/8 agonist Resiquimod causes myocarditis and dilated cardiomyopathy in a new mouse model of autoimmune heart disease. Disease models & mechanisms. 2017;10:259-70.

[34] Kroner A, Greenhalgh AD, Zarruk JG, Passos Dos Santos R, Gaestel M, David S. TNF and increased intracellular iron alter macrophage polarization to a detrimental M1 phenotype in the injured spinal cord. Neuron. 2014;83:1098-116.

[35] Masuda J, Shigehiro T, Matsumoto T, Satoh A, Mizutani A, Umemura C, et al. Cytokine Expression and Macrophage Localization in Xenograft and Allograft Tumor Models Stimulated with Lipopolysaccharide. International journal of molecular sciences. 2018;19.

[36] Pedraza-Brindis EJ, Sanchez-Reyes K, Hernandez-Flores G, Bravo-Cuellar A, Jave-Suarez LF, Aguilar-Lemarroy A, et al. Culture supernatants of cervical cancer cells induce an M2 phenotypic profile in THP-1 macrophages. Cellular immunology. 2016;310:42-52.

[37] Zhang Y, Sime W, Juhas M, Sjolander A. Crosstalk between colon cancer cells and macrophages via inflammatory mediators and CD47 promotes tumour cell migration. European journal of cancer. 2013;49:3320-34.

[38] Guilliams M, Bruhns P, Saeys Y, Hammad H, Lambrecht BN. The function of Fcγ receptors in dendritic cells and macrophages. Nature reviews Immunology. 2014;14:94- 108.

[39] Zhang Z, Ohto U, Shibata T, Taoka M, Yamauchi Y, Sato R, et al. Structural Analyses of Toll-like Receptor 7 Reveal Detailed RNA Sequence Specificity and Recognition Mechanism of Agonistic Ligands. Cell reports. 2018;25:3371-81 e5. [40] Lombardo E, Alvarez-Barrientos A, Maroto B, Bosca L, Knaus UG. TLR4- Mediated Survival of Macrophages Is MyD88 Dependent and Requires TNF- Autocrine Signalling. The Journal of Immunology. 2007;178:3731-9.

[41] Joshi T, Butchar JP, Tridandapani S. Fcγ receptor signaling in phagocytes.International journal of hematology. 2006;84:210-6.

[42] Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer research. 1986;46:6387-92.

[43] Budzynski W, Radzikowski C. Cytotoxic cells in immunodeficient athymic mice. Immunopharmacology and immunotoxicology. 1994;16:319-46.

[44] Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nature medicine. 2013;19:1264-72.

[45] Kulkarni A, Chandrasekar V, Natarajan SK, Ramesh A, Pandey P, Nirgud J, et al. A designer self-assembled supramolecule amplifies macrophage immune responses against aggressive cancer. Nature Biomedical Engineering. 2018;2:589-99. [46] Leimgruber A, Berger C, Cortez-Retamozo V, Etzrodt M, Newton AP, Waterman P, et al. Behavior of Endogenous Tumor-Associated Macrophages Assessed In Vivo Using a Functionalized Nanoparticle. Neoplasia. 2009;11:459-IN4.

[47] Bian Z, Shi L, Guo Y-L, Lv Z, Tang C, Niu S, et al. Cd47-Sirpα interaction and IL- 10 constrain inflammation-induced macrophage phagocytosis of healthy self-cells. Proceedings of the National Academy of Sciences. 2016;113:E5434.

[48] Pander J, Heusinkveld M, van der Straaten T, Jordanova ES, Baak-Pablo R, Gelderblom H, et al. Activation of tumor-promoting type 2 macrophages by EGFR- targeting antibody cetuximab. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011;17:5668-73.

[49] Su S, Zhao J, Xing Y, Zhang X, Liu J, Ouyang Q, et al. Immune Checkpoint Inhibition Overcomes ADCP-Induced Immunosuppression by Macrophages. Cell. 2018;175:442-57 e23.

[50] Shen X, Burguillos MA, Osman AM, Frijhoff J, Carrillo-Jimenez A, Kanatani S, et al. Glioma-induced inhibition of caspase-3 in microglia promotes a tumor-supportive phenotype. Nature immunology. 2016;17:1282-90.

Chapter 4

[1] Jaiswal S, Chao MP, Majeti R, Weissman IL. Macrophages as mediators of tumor immunosurveillance. Trends in immunology. 2010;31:212-9.

[2] Fink MY, Maloney J, Keselman A, Li E, Menegas S, Staniorski C, et al. Proliferation of Resident Macrophages Is Dispensable for Protection during Giardia duodenalis Infections. ImmunoHorizons. 2019;3:412-21.

[3] Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nature reviews Immunology. 2008;8:958-69.

[4] Espinosa V, Rivera A. First Line of Defense: Innate Cell-Mediated Control of Pulmonary Aspergillosis. Frontiers in microbiology. 2016;7.

[5] Guha I, Naskar D, Sen M. Macrophage as a mediator of immune response: Sustenance of immune homeostasis. 2015.

[6] Davies LC, Jenkins SJ, Allen JE, Taylor PR. Tissue-resident macrophages. Nature immunology. 2013;14:986-95.

[7] Vaananen HK, Laitala-Leinonen T. Osteoclast lineage and function. Archives of biochemistry and biophysics. 2008;473:132-8.

[8] Wolf SA, Boddeke HWGM, Kettenmann H. Microglia in Physiology and Disease. Annual Review of Physiology. 2017;79:619-43.

[9] Chistiakov DA, Bobryshev YV, Orekhov AN. Changes in transcriptome of macrophages in atherosclerosis. Journal of cellular and molecular medicine. 2015;19:1163-73.

[10] Kozicky LK, Sly LM. Depletion and Reconstitution of Macrophages in Mice. In: Allen IC, editor. Mouse Models of Innate Immunity: Methods and Protocols. New York, NY: Springer New York; 2019. p. 101-12.

[11] Moughon DL, He H, Schokrpur S, Jiang ZK, Yaqoob M, David J, et al. Macrophage Blockade Using CSF1R Inhibitors Reverses the Vascular Leakage Underlying Malignant Ascites in Late-Stage Epithelial Ovarian Cancer. Cancer research. 2015;75:4742-52.

[12] Xaus J, Comalada M, Valledor AF, Cardó M, Herrero C, Soler C, et al. Molecular Mechanisms Involved in Macrophage Survival, Proliferation, Activation or Apoptosis. Immunobiology. 2001;204:543-50.

[13] Shobaki N, Sato Y, Suzuki Y, Okabe N, Harashima H. Manipulating the function of tumor-associated macrophages by siRNA-loaded lipid nanoparticles for cancer immunotherapy. Journal of Controlled Release. 2020;325:235-48.

[14] Kuhn DA, Vanhecke D, Michen B, Blank F, Gehr P, Petri-Fink A, et al. Different endocytotic uptake mechanisms for nanoparticles in epithelial cells and macrophages. Beilstein journal of nanotechnology. 2014;5:1625-36.

[15] Pacheco P, White D, Sulchek T. Effects of Microparticle Size and Fc Density on Macrophage Phagocytosis. PLoS ONE. 2013;8:e60989.

[16] Champion JA, Walker A, Mitragotri S. Role of Particle Size in Phagocytosis of Polymeric Microspheres. Pharmaceutical research. 2008;25:1815-21.

[17] Freeman SA, Grinstein S. Phagocytosis: receptors, signal integration, and the cytoskeleton. Immunological Reviews. 2014;262:193-215.

[18] Ying W, Cheruku PS, Bazer FW, Safe SH, Zhou B. Investigation of macrophage polarization using bone marrow derived macrophages. Journal of visualized experiments : JoVE. 2013:50323.

[19] Weiskopf K, Ring AM, Ho CCM, Volkmer J-P, Levin AM, Volkmer AK, et al. Engineered SIRPα Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies. Science. 2013;341:88.

[20] Shi Y, Lammers T. Combining Nanomedicine and Immunotherapy. Accounts of chemical research. 2019.

[21] Gaudino SJ, Kumar P. Cross-Talk Between Antigen Presenting Cells and T Cells Impacts Intestinal Homeostasis, Bacterial Infections, and Tumorigenesis. Frontiers in immunology. 2019;10:360-.

[22] Engel JE, Chade AR. Macrophage polarization in chronic kidney disease: a balancing act between renal recovery and decline? American Journal of Physiology-Renal Physiology. 2019;317:F1409-F13.

[23] Lavine KJ, Pinto AR, Epelman S, Kopecky BJ, Clemente-Casares X, Godwin J, et al. The Macrophage in Cardiac Homeostasis and Disease: JACC Macrophage in CVD Series (Part 4). J Am Coll Cardiol. 2018;72:2213-30.

[24] Tacke F, Zimmermann HW. Macrophage heterogeneity in liver injury and fibrosis. Journal of hepatology. 2014;60:1090-6.

[25] Mammana S, Fagone P, Cavalli E, Basile MS, Petralia MC, Nicoletti F, et al. The Role of Macrophages in Neuroinflammatory and Neurodegenerative Pathways of Alzheimer's Disease, Amyotrophic Lateral Sclerosis, and Multiple Sclerosis: Pathogenetic Cellular Effectors and Potential Therapeutic Targets. International journal of molecular sciences. 2018;19:831.

[26] Na YR, Stakenborg M, Seok SH, Matteoli G. Macrophages in intestinal inflammation and resolution: a potential therapeutic target in IBD. Nature Reviews Gastroenterology & Hepatology. 2019;16:531-43.